Assessment of target organ damage in the evaluation and follow-up of hypertensive patients: where do we stand?
- PMID: 24088283
- PMCID: PMC8033957
- DOI: 10.1111/jch.12185
Assessment of target organ damage in the evaluation and follow-up of hypertensive patients: where do we stand?
Abstract
Hypertension is associated with damage to the heart, kidneys, and vascular tree. Assessment of target organ damage (TOD) allows better prediction of cardiovascular risk than conventional risk assessment. Regression of TOD during antihypertensive treatment, which depends on the blood pressure (BP) reduction and the specific ancillary properties of each drug, may indirectly indicate that BP is well controlled. It is unclear whether regression of TOD during treatment is associated with favorable outcome and should be used as a surrogate endpoint. There is evidence that regression of left ventricular hypertrophy and albuminuria are associated with a favorable outcome. However, recent studies cast doubts on this evidence. Thus, assessment of TOD is important to define cardiovascular risk, but, so far, regression of TOD cannot be regarded as a major surrogate therapeutic target. The present paper will provide a critical overview of the data available in the literature.
©2013 Wiley Periodicals, Inc.
Figures
Comment in
-
Should target organ damage become a therapeutic target?J Clin Hypertens (Greenwich). 2013 Oct;15(10):710-1. doi: 10.1111/jch.12184. Epub 2013 Aug 19. J Clin Hypertens (Greenwich). 2013. PMID: 24088277 Free PMC article. No abstract available.
References
-
- Mancia G, Laurent S, Agabiti‐Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121–2158. - PubMed
-
- Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH‐ESC Practice Guidelines for the Management of Arterial Hypertension: ESH‐ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25:1751–1762. - PubMed
-
- Rothwell PM, Price JF, Fowkes FG, et al. Short‐term effects of daily aspirin on cancer incidence, mortality, and non‐vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379:1602–1612. - PubMed
-
- Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower‐than‐average cholesterol concentrations, in the Anglo‐Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT‐LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–1158. - PubMed
-
- Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–840. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
